Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, characterized by tense bullae on erythematous or normal skin with severe pruritus, predominantly affecting adults over age 70. [1-2] It is caused by IgG autoantibodies targeting hemidesmosomal proteins BP180 and BP230 at the dermal-epidermal junction. [1][3]
1. History
- Pruritus is often the earliest and most prominent symptom — may precede blisters by weeks to months [2][4]
- Characterize blister onset: tense (not flaccid), location, number of new blisters per day, and whether they arise on erythematous or normal-appearing skin [1][3]
- Ask about a prodromal phase: urticarial plaques, eczematous patches, or excoriations without frank blistering (nonbullous BP occurs in >20% of patients) [4]
- Timing relative to new medications — especially DPP-4 inhibitors (gliptins), immune checkpoint inhibitors, loop diuretics [5-7]
- Progression: chronic relapsing-remitting course; spontaneous remission possible but unpredictable [2][8]
- Important negatives: oral/mucosal involvement (present in <30% of BP, unlike pemphigus vulgaris), absence of scarring or milia (distinguishes from epidermolysis bullosa acquisita) [9-10]
2. Alarm Features
- Extensive disease (>10 new blisters/day) — associated with higher morbidity and mortality [11-12]
- Secondary infection of erosions: cellulitis, sepsis (leading cause of death) [13-14]
- Signs of systemic corticosteroid toxicity in elderly patients on treatment (hyperglycemia, delirium, GI bleeding) [11]
- Rapid spread with hemodynamic instability or fever suggesting superinfection
- Mucosal predominance → consider mucous membrane pemphigoid (risk of scarring, blindness) [15-16]
- New neurological symptoms — BP is strongly associated with dementia, Parkinson disease, and stroke [13][17]
3. Medications
Drug-associated BP triggers (review and consider discontinuation):
- DPP-4 inhibitors (gliptins): strongest evidence — vildagliptin, linagliptin, sitagliptin (OR ~2–4) [5-6][18]
- PD-1/PD-L1 checkpoint inhibitors (nivolumab, pembrolizumab) [7][19]
- Loop diuretics (furosemide), aldosterone antagonists (spironolactone) [6-7]
- Anticholinergics, dopaminergic agents, neuroleptics/antipsychotics [6][20]
- Penicillins and derivatives [7]
First-line treatments
- Topical clobetasol propionate 0.05% (10–40 g/day, tapered) — effective and safer than systemic steroids, especially in localized/moderate disease [11][13]
- Oral prednisolone 0.5 mg/kg/day — adequate for most patients; doses >0.75 mg/kg/day offer no additional benefit and increase mortality [11-12]
- Doxycycline 200 mg/day — acceptable blister control with significantly fewer serious adverse events than prednisolone; preferred in frail elderly [21]
Steroid-sparing adjuncts: azathioprine, mycophenolate mofetil, methotrexate, dapsone (evidence limited) [11][13]
Biologics for refractory disease: rituximab, omalizumab, dupilumab (FDA-approved for BP in adults) [22-23]
Contraindicated/caution: Avoid high-dose systemic corticosteroids in elderly with multiple comorbidities when possible — associated with increased mortality [11][13]
4. Diet
- No specific dietary triggers are established for BP
- Adequate protein and caloric intake is important for wound healing in elderly patients with extensive erosions
- Monitor for corticosteroid-induced hyperglycemia — dietary counseling for diabetic patients
- Ensure adequate calcium and vitamin D supplementation if on prolonged systemic corticosteroids
5. Review of Systems
- Skin: pruritus severity, new blister count, erosions, signs of infection (warmth, purulence, odor)
- Neurological: cognitive decline, tremor, gait disturbance, seizures (strong BP-neurological disease association) [13][17]
- Ophthalmologic: eye pain, redness, visual changes (rule out ocular mucous membrane pemphigoid)
- Oral: mouth sores, dysphagia (mucosal involvement)
- Systemic: fever, weight loss, fatigue (infection, malignancy screening)
- Endocrine: polyuria, polydipsia (steroid-induced diabetes)
6. Collateral History and Family History
- Collateral from caregivers is critical — many BP patients have dementia or cognitive impairment and cannot reliably report symptom timeline or medication changes [24-25]
- Medication reconciliation with pharmacy records (especially recent DPP-4 inhibitor or checkpoint inhibitor initiation) [5][7]
- Family history of autoimmune diseases (BP itself is not strongly hereditary, but autoimmune predisposition may be relevant)
- HLA-DQA105 has been associated with DPP-4 inhibitor-induced BP [26]
- Social context: functional status, ability to apply topical medications, caregiver availability (critical for treatment planning) [11][21]
7. Risk Factors
- Age >70 years — strongest demographic risk factor [1][21]
- Neurological diseases: dementia (OR ~4–5), Parkinson disease (OR ~3), stroke (OR ~2.7), epilepsy, multiple sclerosis [13][17]
- Medication exposure: DPP-4 inhibitors, checkpoint inhibitors, loop diuretics, spironolactone, neuroleptics [6-7]
- Immobility and institutionalization [21]
- Diabetes mellitus (partly confounded by DPP-4 inhibitor use) [5][20]
- Psoriasis (independent association reported) [13]
- Low Karnofsky performance score — predicts worse outcomes [12-13]
8. Differential Diagnosis
- Pemphigus vulgaris: flaccid blisters, positive Nikolsky sign, mucosal predominance, intraepidermal acantholysis [9][15]
- Linear IgA bullous dermatosis: "string of pearls" pattern, IgA deposits on DIF; drug-induced (vancomycin) [15][27]
- Epidermolysis bullosa acquisita: acral/mechanical blisters, scarring, milia; dermal-side binding on salt-split skin [11][16]
- Dermatitis herpetiformis: grouped vesicles on extensor surfaces, granular IgA in dermal papillae, celiac association [27]
- Mucous membrane pemphigoid: mucosal predominance with scarring (ocular, oral, genital) [15-16]
- Contact dermatitis / eczema / urticaria: common misdiagnoses in the nonbullous prodromal phase [4]
- Scabies with secondary bullae: especially in institutionalized elderly [14]
- Drug eruption / Stevens-Johnson syndrome / TEN: acute onset, mucosal involvement, systemic toxicity
- Bullous diabeticorum: spontaneous blisters on extremities in diabetics, no autoantibodies
The following diagnostic algorithm from Rook's Dermatology Handbook illustrates the immunofluorescence-based approach to differentiating subepidermal autoimmune blistering diseases:
9. Past Medical History
- Prior episodes of blistering or unexplained pruritus (may represent undiagnosed nonbullous BP) [4]
- Neurological diagnoses: dementia, Parkinson disease, stroke, epilepsy, MS [13][17]
- Diabetes mellitus and current antidiabetic regimen (DPP-4 inhibitor use) [5]
- Active or prior malignancy — especially if on checkpoint inhibitor therapy [19]
- History of osteoporosis, peptic ulcer disease, diabetes (impacts corticosteroid safety)
- Immunosuppression history
- Renal/hepatic function (affects choice of steroid-sparing agents)
10. Physical Exam
- Tense, dome-shaped bullae (1–3 cm) on erythematous or normal skin — hallmark finding [1][3][8]
- Distribution: flexural surfaces of limbs, trunk, groin; may be generalized [10]
- Urticarial plaques, eczematous patches, excoriations (nonbullous phase) [2][4]
- Nikolsky sign negative (positive in pemphigus) [15]
- Erosions with serous or hemorrhagic crusting at sites of ruptured bullae
- Assess for secondary infection: erythema, warmth, purulence, malodor
- Mucosal exam: oral, conjunctival, genital (involved in <30% of BP) [9]
- No scarring or milia (distinguishes from EBA and cicatricial pemphigoid) [10]
- Count new blisters: ≤10/day = moderate; >10/day = severe [11]
- Vital signs: fever (infection), tachycardia, hypotension (sepsis)
11. Lab Studies
- CBC with differential: peripheral eosinophilia is common and supportive [19]
- Anti-BP180 NC16A ELISA: pooled sensitivity ~82%, specificity ~94% — most useful serologic test; levels correlate with disease activity and relapse risk [13][29]
- Anti-BP230 ELISA: lower sensitivity (~59%) but high specificity (~95%); best used as adjunctive/confirmatory [29]
- Combined BP180 + BP230 ELISA sensitivity reaches ~90% [13]
- Total serum IgE: often elevated in BP
- BMP, glucose, HbA1c: baseline before corticosteroid initiation
- LFTs, CBC: baseline before immunosuppressive agents
- TPMT activity: if azathioprine is considered
- Wound culture if secondary infection suspected
12. Imaging
- No specific imaging is required for diagnosis of BP
- Chest X-ray if concern for pneumonia (BP patients have 3× higher pneumonia risk) [13]
- Age-appropriate cancer screening — weak and controversial association with malignancy; routine screening beyond standard guidelines is not recommended [13][30]
- Brain imaging only if new neurological symptoms warrant evaluation
13. Special Tests
- Skin biopsy (lesional): subepidermal blister with eosinophilic infiltrate on H&E — supportive but not specific [11]
- Direct immunofluorescence (DIF) of perilesional skin: gold standard — linear IgG and/or C3 deposits along the basement membrane zone; sensitivity ~91%, specificity ~98% [11][31]
- Indirect immunofluorescence (IIF) on salt-split skin: epidermal-side binding of IgG distinguishes BP from EBA (dermal-side binding) [11]
- C3d immunohistochemistry: comparable diagnostic utility to DIF; can be performed on formalin-fixed tissue [32]
- Bullous Pemphigoid Disease Area Index (BPDAI): validated scoring system for disease severity and treatment response [12]
A proposed "2-out-of-3 rule" for diagnosis: (1) pruritus and/or predominant cutaneous blisters, (2) linear IgG/C3 on DIF, (3) positive epidermal-side staining on IIF salt-split skin [4]
14. ECG
- ECG is not part of the standard BP workup but should be obtained in elderly patients as part of baseline assessment, particularly before initiating systemic corticosteroids
- BP is associated with a 5-fold higher cardiovascular disease mortality; cardiovascular comorbidities are common in this population [14][30][33]
- Monitor for QTc prolongation if using azithromycin or other QT-prolonging agents concurrently
- Corticosteroid-induced hypokalemia may cause arrhythmias — monitor electrolytes
15. Assessment
Severity stratification: [11-12]
- Mild: localized disease, few blisters, manageable pruritus
- Moderate: ≤10 new blisters/day
- Severe/extensive: >10 new blisters/day, widespread involvement
BP is a chronic disease with a 1-year mortality of 20–40%, approximately 2–3× higher than age-matched controls. [13] Death is most commonly due to infection (pneumonia, sepsis) and cardiovascular disease, often compounded by treatment-related adverse effects. [13][30] Atypical/nonbullous presentations (urticarial, eczematous, prurigo-like) are common and frequently misdiagnosed, leading to diagnostic delay. [4]
16. Treatment Plan
Initial stabilization
- Wound care: gentle cleansing, non-adherent dressings, lance large tense bullae with sterile technique (leave roof intact)
- Antihistamines for pruritus (cetirizine, hydroxyzine)
- Discontinue suspected offending medications (DPP-4 inhibitors, checkpoint inhibitors) [5][7]
Pharmacotherapy by severity
- Mild/localized: Topical clobetasol propionate 0.05% to affected areas [3][13]
- Moderate: Whole-body clobetasol propionate (10–30 g/day, tapered over 4 months) OR oral prednisolone 0.5 mg/kg/day OR doxycycline 200 mg/day [11][21]
- Severe/extensive: Whole-body clobetasol propionate 40 g/day (tapered over 12 months) OR oral prednisolone 0.5 mg/kg/day + steroid-sparing agent [11][13]
- Refractory: Rituximab, omalizumab, dupilumab (FDA-approved), IVIG, or JAK inhibitors [22-23]
Steroid-sparing agents (for corticosteroid taper or contraindication): doxycycline, azathioprine, mycophenolate mofetil, methotrexate, dapsone [11][13]
Monitoring on treatment: glucose, blood pressure, bone density (if prolonged steroids); CBC, LFTs (if on immunosuppressants); anti-BP180 levels to guide taper (high levels at discontinuation predict relapse) [13]
17. Disposition
Admission criteria
- Extensive/severe disease (>10 new blisters/day) with inability to manage wound care at home
- Secondary infection with systemic signs (sepsis, cellulitis)
- Significant comorbidities precluding safe outpatient management (frail elderly, dementia, no caregiver)
- Need for initiation of systemic immunosuppression with close monitoring
- Fluid/electrolyte imbalance from extensive skin loss
Discharge criteria
- Disease control achieved (no new blisters for ≥2 weeks)
- Stable on oral regimen with adequate wound care plan
- Caregiver available for topical medication application if needed
Specialist consultation
- Dermatology — all suspected cases for biopsy, DIF, and treatment guidance
- Ophthalmology if ocular symptoms (rule out ocular cicatricial pemphigoid)
- Neurology if new neurological symptoms
- Infectious disease if complicated wound infections
18. Follow Up / Return Precautions
Follow-up timing
- Dermatology within 1–2 weeks of diagnosis for biopsy results and treatment adjustment
- Every 2–4 weeks during active disease until control achieved
- Monthly during taper; every 2–3 months once in remission
- Anti-BP180 ELISA levels can guide taper decisions [13]
Return precautions — instruct patients/caregivers to seek care for:
- New blister flare or worsening pruritus despite treatment
- Signs of skin infection: increasing redness, warmth, pus, fever
- Symptoms of steroid side effects: confusion, blood sugar changes, GI bleeding, leg swelling
- Shortness of breath, chest pain (pneumonia, PE — 3× increased risk) [13]
- Falls, fractures (steroid-induced osteoporosis in elderly)
Expected course: BP is chronic with exacerbations and remissions. Many patients achieve remission within 1–5 years, but relapse is common, particularly if anti-BP180 antibody levels remain elevated at treatment discontinuation. [13] Mortality is significantly elevated in the first year, driven by infection and cardiovascular events. [13][30]
References
1. Bullous Pemphigoid. — Akbarialiabad H, Schmidt E, Patsatsi A, et al. Nature Reviews. Disease Primers. 2025.
2. Bullous Pemphigoid: A Review of Its Diagnosis, Associations and Treatment. — Bernard P, Antonicelli F. American Journal of Clinical Dermatology. 2017.
3. Bullous Pemphigoid. — Bağcı IS, Horváth ON, Ruzicka T, Sárdy M. Autoimmunity Reviews. 2017.
4. Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid. — Meijer JM, Diercks GFH, de Lang EWG, Pas HH, Jonkman MF. JAMA Dermatology. 2019.
5. Exploration of Drugs Associated With the Development of Bullous Pemphigoid: A Nationwide Study. — Kim MJ, Kim BR, Lee KH, et al. The Journal of Dermatology. 2025.
6. Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis. — Liu SD, Chen WT, Chi CC. JAMA Dermatology. 2020.
7. A Systematic Review of Drug-Induced Pemphigoid. — Verheyden MJ, Bilgic A, Murrell DF. Acta Dermato-Venereologica. 2020.
8. Bullous Pemphigoid. — Korman N. Journal of the American Academy of Dermatology. 1987.
9. Bullous Autoimmune Dermatoses. — Hofmann SC, Juratli HA, Eming R. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2018.
10. Evaluation of Clinical Criteria for Diagnosis of Bullous Pemphigoid. — Vaillant L, Bernard P, Joly P, et al. Archives of Dermatology. 1998.
11. Interventions for Bullous Pemphigoid. — Singh S, Kirtschig G, Anchan VN, et al. The Cochrane Database of Systematic Reviews. 2023.
12. International Multicentre Observational Study to Assess the Efficacy and Safety of a 0·5 Mg Kg Per Day Starting Dose of Oral Corticosteroids to Treat Bullous Pemphigoid. — Hébert V, Bastos S, Drenovska K, et al. The British Journal of Dermatology. 2021.
13. Pemphigoid Diseases. — Schmidt E, Zillikens D. Lancet. 2013.
14. Comorbid Diseases in Bullous Pemphigoid: A Population-Based Case-Control Study. — Kim BR, Lee KH, Paik K, et al. The Journal of Dermatology. 2025.
15. Review of Autoimmune Blistering Diseases: The Pemphigoid Diseases. — Daniel BS, Murrell DF. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019.
16. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. — Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Clinical Reviews in Allergy & Immunology. 2018.
17. Bullous Pemphigoid and Its Association With Neurological Diseases: A Systematic Review and Meta-Analysis. — Lai YC, Yew YW, Lambert WC. Journal of the European Academy of Dermatology and Venereology : JEADV. 2016.
18. Association Between DPPs-4 Inhibitors and Bullous Pemphigoid: Reporting Odds Ratio Analysis Using EudraVigilance Database. — Pedrero AC, Aldea-Perona A. Pharmaceuticals. 2025.
19. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review. — Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. JAMA Dermatology. 2022.
20. Association of Statins, Gliptins, and Antipsychotics With Bullous Pemphigoid: A Case-Control Study in the Cretan Population. — Kavvalou E, Krasagakis K, Chlouverakis G, et al. The Journal of Dermatology. 2025.
21. Doxycycline Versus Prednisolone as an Initial Treatment Strategy for Bullous Pemphigoid: A Pragmatic, Non-Inferiority, Randomised Controlled Trial. — Williams HC, Wojnarowska F, Kirtschig G, et al. Lancet. 2017.
22. FDA Orange Book. — FDA Orange Book. 2026.
23. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update. — Karakioulaki M, Eyerich K, Patsatsi A. American Journal of Clinical Dermatology. 2024.
24. Demographics and Autoantibody Profiles of Pemphigoid Patients With Underlying Neurologic Diseases. — Messingham KN, Miller AD, Narayanan NS, Connell SJ, Fairley JA. The Journal of Investigative Dermatology. 2019.
25. A Population-Based Study of the Association Between Bullous Pemphigoid and Neurologic Disorders. — Brick KE, Weaver CH, Savica R, et al. Journal of the American Academy of Dermatology. 2014.
26. Association of Genetic Variants of HLA-DQA1 With Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors. — Ozeki T, Muramatsu K, Yoshimoto N, et al. The Journal of Investigative Dermatology. 2023.
27. Subepithelial Autoimmune Blistering Dermatoses: Clinical Features and Diagnosis. — Montagnon CM, Tolkachjov SN, Murrell DF, Camilleri MJ, Lehman JS. Journal of the American Academy of Dermatology. 2021.
28. Immunobullous diseases. — Rook's Dermatology Handbook. 2023.
29. Sensitivity and Specificity of ELISA Tests Detecting BP180 and BP230 Antibodies in the Diagnosis of Bullous Pemphigoid: A Systematic Review and Meta-Analysis. — Grochowska-Rak M, Kulig K, Grabowska A, et al. International Journal of Dermatology. 2025.
30. Risk of All-Cause Mortality, Cardiovascular Disease Mortality, and Cancer Mortality in Patients With Bullous Pemphigoid. — Shen WC, Chiang HY, Chen PS, et al. JAMA Dermatology. 2022.
31. Comparative Study of Direct and Indirect Immunofluorescence and of Bullous Pemphigoid 180 and 230 Enzyme-Linked Immunosorbent Assays for Diagnosis of Bullous Pemphigoid. — Sárdy M, Kostaki D, Varga R, Peris K, Ruzicka T. Journal of the American Academy of Dermatology. 2013.
32. Comparison of C3d Immunohistochemical Staining to Enzyme-Linked Immunosorbent Assay and Immunofluorescence for Diagnosis of Bullous Pemphigoid. — Wang LL, Moshiri AS, Novoa R, et al. Journal of the American Academy of Dermatology. 2020.
33. A Retrospective Consecutive Case-Series Study on the Effect of Systemic Treatment, Length of Admission Time, and Co-Morbidities in 98 Bullous Pemphigoid Patients Admitted to a Tertiary Centre. — Kibsgaard L, Bay B, Deleuran M, Vestergaard C. Acta Dermato-Venereologica. 2015.